Seven IPOs raising at least $100 million are currently scheduled for the week ahead, in what could be one of the busiest weeks for sizable offerings since 2021. Notably, only one other week over the past four years has produced seven $100 million-plus IPOs,...read more
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, announced terms for its IPO on Wednesday. The Millbrae, CA-based company plans to raise $300 million by offering 17.6 million shares at a price range of $16 to $18. At...read more
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. However, the deal size is likely a placeholder for an offering that we estimate...read more
US IPO Week Ahead: At least 7 sizable IPOs teed up in one of the busiest weeks in four years
Seven IPOs raising at least $100 million are currently scheduled for the week ahead, in what could be one of the busiest weeks for sizable offerings since 2021. Notably, only one other week over the past four years has produced seven $100 million-plus IPOs,...read more
Immuno-responsive cancer biotech Eikon Therapeutics sets terms for $300 million IPO
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, announced terms for its IPO on Wednesday. The Millbrae, CA-based company plans to raise $300 million by offering 17.6 million shares at a price range of $16 to $18. At...read more
US IPO Weekly Recap: Aktis Oncology leads as first sizable 2026 IPO
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Immuno-responsive cancer biotech Eikon Therapeutics files for an estimated $300 million IPO
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. However, the deal size is likely a placeholder for an offering that we estimate...read more